You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 499 Myeloid diversity in hormone receptor positive breast cancer reveals myeloid and lymphoid signaling pathways that correlate with T cell inhibition

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
499 Myeloid diversity in hormone receptor positive breast cancer reveals myeloid and lymphoid signaling pathways that correlate with T cell inhibition

Authors

  • Chenyi Gu Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA Brigham and Women’s Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Kenichi Shimada Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Lukas Kania Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Daniel E Michaud Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Brigham and Women’s Hospital, Brookline, MA, USA PubMed articlesGoogle scholar articles
  • Madeline G Townsend Brigham and Women’s Hospital, Brookline, MA, USA PubMed articlesGoogle scholar articles
  • Jennifer L Guerriero Brigham and Women’s Hospital, Boston, MA, USA Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA PubMed articlesGoogle scholar articles

Citation

Gu C, Shimada K, Kania L, et al
499 Myeloid diversity in hormone receptor positive breast cancer reveals myeloid and lymphoid signaling pathways that correlate with T cell inhibition
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0499

Publication history

  • First published November 2, 2023.
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.